Task Force Report on Brain Involvement in Antiphospholipid Syndrome

Chapter

Abstract

Many neurological manifestations have been described in Antiphospholipid Syndrome (APS). More work is needed to identify those individuals with antiphospholipid antibodies (aPL) who are at greatest risk for nervous system manifestations. Antiphospholipid antibodies are established risk factors for a first ischemic stroke in patients with and without systemic lupus erythematosus (SLE), and recurrent cerebrovascular ischemia, particularly in adults with SLE; however, subgroups of these patients at high-risk for recurrent events have not been clearly identified. Persistently positive aPL are associated with cognitive dysfunction in adults with SLE. There is no evidence to support an association between aPL and headache. Antiphospholipid antibodies may be associated with a worse clinical course in adults with SLE who also have Multiple Sclerosis (MS) or an “MS-like” illness and anticardiolipin antibody IgM may be increased during an exacerbation in adults with definite MS, but without SLE. Antiphsopholipid antibodies are associated with seizures and epilepsy in patients with and without SLE. Particular attention needs to be paid to differentiating those manifestations that are mediated through a thrombotic mechanism and those that are mediated through another immune-mediated mechanism. Additional studies that help determine the pathophysiology of aPL-mediated nervous system effects are needed to target appropriate therapies.

Keywords

Toxicity Ischemia Migraine Dementia Stratification 

References

  1. 1.
    Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res. 2002;90:29–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus. 2003;12:508–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruiz-Irastorza G, Khamashta MA, Hughes GR. Hughes syndrome crosses boundaries. Autoimmun Rev. 2002;1:43–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Roubey RA, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet. 1997;350:1491–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8:127–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Katzav A, Litvinjuk Y, Pick CG, et al. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res. 2006;169:289–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Meroni PL, Raschi E, Testoni C. Endothelium as a target for antiphospholipid antibodies and for therapeutical intervention. Autoimmun Rev. 2002;1:55–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Matsuura E, Kobayashi K, Yasuda T, Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus. 1998;7:S135–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:46–50.Google Scholar
  11. 11.
    Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992;90:1105–9.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Katzav A, Pick CG, Korczyn AD, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10:496–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Shrot S, Katzav A, Korczyn AD, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 2002;11:736–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Shoenfeld Y, Nahum A, Korczyn AD, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003;12:436–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Correale J, Villa A. Cellular elements of the blood–brain barrier. Neurochem Res. 2009;34:2067–77.PubMedCrossRefGoogle Scholar
  16. 16.
    Rabchevsky AG, Degos JD, Dreyfus PA. Peripheral injections of Freund’s adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis. Brain Res. 1999;832:84–96.PubMedCrossRefGoogle Scholar
  17. 17.
    Brey RL. Management of the neurological manifestations of APS—what do the trials tell us? Thromb Res. 2004;114:489–99.PubMedCrossRefGoogle Scholar
  18. 18.
    Urbanus RT, Siegerink B, Roest M, Rosendall FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol. 2009;8:998–1005.PubMedCrossRefGoogle Scholar
  19. 19.
    Tohgi H, Takahashi H, Kashiwaya M, Watanabe K, Hayama K. The anticardiolipin antibody in elderly stroke patients: its effects on stroke types, recurrence, and the coagulation-fibrinolysis system. Acta Neurol Scand. 1994;90:86–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995;38:119–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122:e1100–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Angelini L, Ravelli A, Caporali R, et al. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics. 1994;94:500–3.PubMedGoogle Scholar
  23. 23.
    Miyaki SL, Atsumi MD, Branch DW, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295–306.CrossRefGoogle Scholar
  24. 24.
    Cervera R, Khamashta MD, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299–308.CrossRefGoogle Scholar
  25. 25.
    Hanly JG, Hong C, Smith S, Fisk JK. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Menon S, Jameson-Shortall E, Neuman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–41.PubMedCrossRefGoogle Scholar
  27. 27.
    McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64:297–303.PubMedCrossRefGoogle Scholar
  28. 28.
    Tomietto P, Annese V, D’agostino S, et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 2007;57:1461–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Meji-Romero R, Garcia-Carrasco M, Galarza-Maldonado C, et al. Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients. Clin Rheumatol. 2008;27:891–7.CrossRefGoogle Scholar
  30. 30.
    Tietjen GE, Day M, Norris L, et al. Role of anticardiolipin antibodies in young persons with a migraine and transient focal neurologic events. Neurology. 1998;50:1433–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Montalban J, Cervera R, Font J, et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology. 1992;42:681–2.PubMedCrossRefGoogle Scholar
  32. 32.
    Bidot CJ, Horstmann LL, Jimenez JJ, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7:36.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Karussi D, Leker RR, Ashkenazi A, et al. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44:629–34.CrossRefGoogle Scholar
  34. 34.
    Appenzeller S, Cendes F, Costallat LTL. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63:1808–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37:568–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Liou HH, Wang CR, Chen CJ, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus. 1996;5:307–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Peltola JT, Haapala A, Isojarvi JI, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new onset seizure disorders. Am J Med. 2000;103:33–7.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Neurology and Sagol Center for Neuroscience, Sheba Medical CenterTel Aviv UniversityTel AvivIsrael
  2. 2.Sections of Rheumatology and Neurology, Department of PediatricsTexas Children’s HospitalHoustonUSA
  3. 3.Department of NeurologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations